Moderna, Inc. remains under pressure in 2025, despite recent next-gen COVID vaccine approval & cancer vaccine trial. Learn ...
With world leaders set to gather in Brazil for COP30 in November, new analysis from an international team of climate policy ...
The 2025 ESMO annual meeting featured a urothelial carcinoma proffered paper session and a presentation by Dr. Maria De Santis discussing POTOMAC, a phase 3, randomized, open-label, trial of ...
Advances in mass spectrometry and chromatography are enhancing pesticide residue analysis, focusing on exposomics and risk assessment for improved food safety. Ion chromatography is evolving with new ...
Abstract: Complex construction environments can interfere with ground-based synthetic aperture radar (GB-SAR) deformation monitoring, potentially leading to missed or false alarms. Current research on ...
Novartis has spent considerable time and energy building its presence in the IgA nephropathy (IgAN) disease area, and now | ...
EyePoint faces clinical, commercial hurdles despite DME, AMD progress and solid funding through 2027. Read why EYPT stock is ...
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ( ...
With the 2025 European Society of Medical Oncology (ESMO) Congress kicking off on Friday, October 17, in Berlin, Germany, Targeted Oncology is bringing you background on the most exciting abstracts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback